Anti-CD300a Antibody [MEM-260] (A281147)

Anti-CD300a Antibody [MEM-260]

Mouse monoclonal [MEM-260] antibody to CD300a.

This antibody recognises human CD300a, otherwise known as IRp60 or inhibitory receptor protein 60, CD300a is a ~60 kDa transmembrane glycoprotein expressed by natural killer cells (NK), T and B cell subsets, monocytes, neutrophils, macrophages, granulocytes, dendritic cells (DC) and mast cells.Cross-linking of CD300a on NK results in a down-regulation of their cytolytic activity, whilst cross-linking of CD300a on mast cells, inhibits IgE-induced degranulation and SCF-mediated survival. Furthermore, cross-linking of CD300a on the surface of eosinophils has been shown to significantly inhibit their survival, chemotaxis and activation in response to certain inflammatory cytokines, whilst eosinophil-derived MBP (major basic protein) and EDN (neurotoxin), can down-regulate CD300a expression on mast cells in vitro (http://www.ncbi.nlm.nih.gov/pubmed/16339535).

WB, Flow Cytometry

Use 10µl of the suggested working dilution to label 1x10⁶ cells in 100µl.

Human

Human HPB acute lymphoid leukaemia cell line.

Mouse

Monoclonal

MEM-260

IgG1

1 mg/ml

Approximately 60 kDa in HPB cell lysates under non-reducing conditions.

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti Human CD300a antibody, clone MEM-260 recognizes human CD300a, otherwise known as IRp60 or inhibitory receptor protein 60, CD300a is a ~60 kDa transmembrane glycoprotein expressed by natural killer cells (NK), T and B cell subsets, monocytes, neutrophils, macrophages, granulocytes, dendritic cells (DC) and mast cells.Cross-linking of CD300a on NK results in a down-regulation of their cytolytic activity, whilst cross-linking of CD300a on mast cells, inhibits IgE-induced degranulation and SCF-mediated survival. Furthermore, cross-linking of CD300a on the surface of eosinophils has been shown to significantly inhibit their survival, chemotaxis and activation in response to certain inflammatory cytokines, whilst eosinophil-derived MBP (major basic protein) and EDN (neurotoxin), can down-regulate CD300a expression on mast cells in vitro (http://www.ncbi.nlm.nih.gov/pubmed/16339535).